Last Week Tonight in Biopharma: Week of April 27th, 2026
Sun Pharma buying Organon, AstraZeneca's dance with the ODAC, Intellia pays the "gene therapy tax", and IPOs are back!
Welcome back to Last Week Tonight in BioPharma (LWTB). What a week! I had a hard time pairing this one down given all the interesting activity we saw. Many deals, data readouts, and strategic updates left on the cutting room floor.
This week, Sun Pharma dropped $11.75B on Organon in a rare India ➡️ US deal, AstraZeneca had a split ODAC day, and Intellia lands the first in vivo gene editing drug to register a positive Phase 3 readout but no one told the stock price. Meanwhile, the FDA is running fast to make real-time clinical trials standard practice, Lilly continues its deal spree, and IPO markets are looking healthy again.
All that and more below. Let’s get into it!
If you subscribe to Big Pharma Sharma (BPS) for LWTB and you like what you read, consider upgrading to paid to read my best work.
For instance, this week I wrote an essay about prediction markets for clinical trial outcomes, comparing them to sports betting markets to learn about their limitations, and discuss why these types of markets are likely to be a net negative for drug makers and patients.
If you’re not ready to commit to being a paid subscriber, but still want to support my work, you can always show your appreciation by buying me drink 😉
📡 PRESS RELEASE DECODER
What the press releases actually mean
AstraZeneca’s Split ODAC Day — Camizestrant 6-3 Against, Truqap 7-1 In Favor
📅 Date: 2026-04-30 | 🏢 Company: AstraZeneca ( AZN 0.00%↑ ) | 💊 Drug/Asset: Camizestrant (SERD), Truqap (capivasertib, AKT inhibitor) | 🏷 Event Type: FDA ODAC Votes
AstraZeneca faced two ODAC votes on the same day (the committee’s first meeting in nine months) and walked away with a split decision. In the morning session, ODAC voted 6-3 against the benefit-risk profile of camizestrant, an oral SERD, for HR+/HER2- metastatic breast cancer. In the afternoon, the same committee voted 7-1 (one abstention) in favor of Truqap (capivasertib) plus abiraterone and prednisone for PTEN-deficient metastatic hormone-sensitive prostate cancer.
The camizestrant rejection wasn’t a straightforward efficacy dispute, it was a rejection of AstraZeneca’s entire proposed treatment paradigm. The SERENA-6 trial used circulating tumor DNA (ctDNA) monitoring to detect ESR1 mutations while patients were still responding to first-line therapy (aromatase inhibitor + CDK4/6 inhibitor), then switched them to camizestrant before radiographic disease progression. The trial showed a 56% PFS improvement, median 16.0 months vs. 9.2 months for patients who stayed on the aromatase inhibitor. But OS data were immature with no benefit signal, the control arm didn’t allow crossover to camizestrant, and only 14% of control patients received any oral SERD in subsequent treatment.
The FDA’s core objection was that the trial doesn’t answer whether switching early is better than switching at progression. As FDA reviewer Mirat Shah put it, “the biggest concern is that approving camizestrant would include the endorsement of a treatment paradigm that does not have established clinical benefit.” The agency also flagged the precedent risk, that biomarker-guided early switching could proliferate across tumor types without evidence it actually extends lives. Multiple ODAC members agreed that ESR1 mutation detection hasn’t been proven as a predictive biomarker (indicating treatment will help) vs. merely a prognostic one (indicating disease is worsening regardless). The patient representative was the most direct: “I really wonder if we are again exploiting the hope of women with metastatic breast cancer that somehow, if they’d known earlier, the trajectory of the disease would be different.”
The Truqap vote was more straightforward. CAPItello-281 showed radiographic PFS of 33.2 months vs. 25.7 months (HR 0.81) with capivasertib added to abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. OS was immature (HR 0.90, not significant). FDA flagged toxicity concerns like hyperglycemia, rash, discontinuations, and deaths, and questioned whether the ~7.5-month PFS gain justified the added burden in an early, minimally symptomatic population. But the panel concluded that the unmet need in PTEN-deficient disease and evidence of target engagement were sufficient, with physicians expected to exercise discretion in patient selection. The single no-vote (Brian Rini, Vanderbilt) argued the benefit was too modest relative to the toxicity profile.
🧠 BPS Take: The split decision is less about two different drugs and more about two fundamentally different questions the FDA is wrestling with. The camizestrant vote was about whether the strategy of acting on a molecular signal before imaging shows progression is ready for primetime. The FDA essentially said: “you’ve shown that switching early extends PFS, but you haven’t shown it’s better than switching at progression, because you didn’t let the control arm access the drug”. That’s a very fair criticism, and I would be curious to see the communications between the FDA and AZN leading up to the launch of the study to better understand how far AZN strayed from the FDA’s guidance. Nonetheless, it is a novel effort by AZN to test switching upon ctDNA progression of a high frequency mutation. Pushing forth novel treatment paradigms is tough business and there are higher risks of their being bumps in the road. AZN may need to re-run this with a crossover-permitted design or wait for OS maturation, both of which cost lots of years and dollars.
What’s interesting is the contrast in how ODAC evaluated “meaningful benefit” across the two votes. In breast cancer, a 6.8-month PFS gain with a novel biomarker-guided paradigm wasn’t enough without OS. In prostate cancer, a 7.5-month PFS gain with an acknowledged toxicity burden passed 7-1. This feels like a broader commentary on where these two diseases are. Breast cancer has a deep bench of endocrine options and ODAC is fatigued by PFS-only approvals in that space, while PTEN-deficient mHSPC is a genomically defined population with genuinely limited options.
AZN will likely get the TRUQAP approval. For camizestrant, it wouldn’t be unprecedented for it to be approved in some fashion, however the negative ODAC vote, higher bar in breast cancer, and study design deficiencies pointed out in the meeting would make me think otherwise.
FDA Approves Arvinas’ Veppanu — First-Ever PROTAC Reaches Market, But Nobody Wants to Sell It
📅 May 1 | 🏢 Arvinas ( ARVN 0.00%↑ ), Pfizer ( PFE 0.00%↑ ) | 💊 Veppanu (vepdegestrant) | 🏷️ Approval
The FDA approved Veppanu (vepdegestrant), a first-in-class PROTAC (proteolysis-targeting chimera), for second-line treatment of ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. PROTACs work by hijacking the cell’s natural waste disposal system to degrade disease-driving proteins — a fundamentally different mechanism than traditional drugs that block or activate targets.
But the approval comes with an unusual asterisk. Neither Arvinas nor its partner Pfizer plan to commercialize it themselves. The two companies originally had a 50-50 development and commercialization deal signed in 2021, envisioning a broad ER+ breast cancer franchise. When VERITAC-2 data narrowed the addressable market to just ESR1-mutated patients in the second-line setting, the economics of the partnership collapsed. Pfizer, for whom a niche monotherapy doesn’t move the needle, effectively walked away from commercialization. Arvinas, which has laid off nearly half its workforce across two rounds of cuts in 2025 and has no commercial infrastructure, can’t launch it alone. In September 2025, both companies agreed to out-license commercialization to a third party. They submitted the NDA to FDA anyway. As of the approval date, no commercialization partner has been announced — CEO Teel says one is expected “in the coming weeks.”
🧠 BPS Take: This is a genuinely strange moment. The first PROTAC ever approved by the FDA has no one lined up to sell it. This should be a much bigger moment, but the commercial story is a cautionary tale about what happens when your data narrows your label to a sliver of your original thesis. Arvinas stock popped ~7%, but the company is clearly pivoting its identity toward its earlier-stage PROTAC pipeline in Parkinson’s (ARV-102), NHL (ARV-393), and KRAS-driven solid tumors (ARV-806). I’m curious to see who picks this asset up and for how much. There are not many de-risked assets in oncology up for sale, albeit this one being in a much smaller market than originally anticipated. For whoever picks up the commercialization rights, the question is whether a first-in-class PROTAC in a narrow ESR1-mutant niche can separate from existing oral SERDs and build a meaningful commercial business.
Intellia Posts First Positive Phase 3 for In Vivo Gene Editing — Stock Down ~7% Since
📅 April 27 | 🏢 Intellia Therapeutics ( NTLA 0.00%↑ ) | 💊 Lonvo-z (lonvoguran ziclumeran) | 🏷️ Data Readout
Intellia reported positive Phase 3 HAELO results for lonvo-z in hereditary angioedema (HAE), marking the first successful Phase 3 trial for any in vivo CRISPR gene editing therapy globally. A single dose of lonvo-z reduced HAE attacks by 87% vs. placebo (p<0.0001) over a six-month evaluation period. 62% of lonvo-z patients were completely attack-free and therapy-free vs. 11% on placebo. Safety was clean — all adverse events mild or moderate, no serious AEs in the treatment arm. Intellia has initiated a rolling BLA submission and is targeting a U.S. launch in H1 2027.
🧠 BPS Take: This is a historic milestone, no doubt. An in vivo gene editing therapy registered a positive Phase 3 study. But the market’s reaction (stock down 7% as of this writing) tells a more nuanced story. Specifically, I think it reflects the “cell and gene therapy tax”. Lonvo-z’s efficacy is essentially identical to Takeda’s Takhzyro (lanadelumab), which also delivers 87% attack rate reduction with a nearly identical mean monthly attack rate (0.26 for lonvo-z vs. 0.3 for Takhzyro). The difference is that lonvo-z is a single IV infusion (a one time potential cure) and Takhzyro requires injections every 2–4 weeks for life. How will the rest of the stakeholders in the market view this? If you’re Intellia, you want them to see this as a curative therapy for a very serious illness, something no other competitor can claim. But perhaps if you are a payer or a competitor, you can look at lonvo-z and say it’s mostly an expensive convenience advantage. The aforementioned “tax” shows up on the efficacy line of a cell or gene therapy’s therapeutic product profile. While the lifetime expense of getting this drug vs. taking several injections very two to four weeks, favors the one-time treatment, the near-term financing of a likely $400K+ gene-editing drug is a massive pill for any payer to swallow. Especially if the efficacy is not numerically all that different from cheaper (albeit lifetime) therapies.
For cell and gene therapies to justify the pricing and payer negotiation headaches that come with one-time treatments, the market increasingly expects a big shift in outcomes. For other gene editing companies, the lesson here is indication selection and product strategy planning early on, before you go down the road of committing to a lead clinical asset or pivotal program, is paramount.
Intellia also announced a $180M equity raise at $10.75/share simultaneously with the data, diluting shareholders right at the moment of maximum attention. The science delivered exactly what it needed to. The question is whether the commercial math works in a world where matching existing efficacy with better convenience may not be enough to command gene therapy economics.
Summit’s Harmoni-3 Interim Miss Sends Stock Down 25% — Ivonescimab’s Global Story Gets Murkier
📅 April 30 | 🏢 Summit Therapeutics ( SMMT 0.00%↑ ) | 💊 Ivonescimab | 🏷️ Data Readout
The squamous cohort of Summit’s Harmoni-3 trial — evaluating ivonescimab (PD-1/VEGF bispecific) plus chemo vs. Keytruda plus chemo in first-line metastatic NSCLC — missed statistical significance on PFS at a recently added interim analysis. The independent data monitoring committee recommended the study continue as planned. Summit noted the interim had a “meaningfully higher bar” than the final PFS analysis due to minimal alpha spent. Final PFS and interim OS readouts are still expected H2 2026.
🧠 BPS Take: Summit tried to add an interim analysis to accelerate a potential FDA conversation, and the bet didn’t pay off. I generally think it is a red flag when companies start rejiggering their statistical analysis plan mid study. The high statistical bar (likely ~0.001 alpha) means this miss doesn’t necessarily predict failure of the final readout, but it does mean the PFS effect size in the global trial may be weaker than what Akeso showed in the China-only studies. This was a big fear behind the entire thesis of Summit as a company. They are playing the China clinical data arbitrage game, but will China data look as good in a global (more western) population? Folks like Kailera, who recently IPO’d, pushing this same strategy with a portfolio of Chinese GLP-1s should take note.
The stakes for the Harmoni-6 (China) OS update at ASCO’s plenary session just got significantly higher. If OS is strong, it buffers some of the negative sentiment from this latest PFS slip. However if the OS disappoints, the PFS slip starts to feel like the canary in the coal mine. Merck, BMS, Pfizer and others who have flocked to PD-1xVEGF are all watching closely.
🌐 CONNECTING THE DOTS
When the outside world meets biopharma
FDA Commissioner Makary Launches Real-Time Trial Monitoring Pilot
📅 Date: 2026-04-28 | 🏢 Company: POLICY/MACRO | 💊 Drug/Asset: N/A | 🏷 Event Type: FDA Policy / Regulatory Reform
The FDA announced two proof-of-concept real-time clinical trials (RTCTs) that are already running, plus a Request for Information (RFI) for a broader pilot program launching this summer.
AstraZeneca is conducting the Phase 2 TRAVERSE trial testing Calquence (BTK inhibitor) + AbbVie’s Venclexta + rituximab in treatment-naïve mantle cell lymphoma. The FDA confirmed it has already received and validated real-time safety signals from this trial through software company Paradigm Health. Amgen is running a Phase 1b trial of Imdelltra (tarlatamab), its DLL3 T-cell engager already approved for extensive-stage SCLC, in limited-stage small cell lung carcinoma (STREAM-SCLC).
The FDA receives aggregated signals only, including adverse event rates, tumor response percentages, and pre-agreed efficacy endpoints. No raw patient-level data. Individual records stay with the sponsor. FDA Chief AI Officer Jeremy Walsh: “We’re not interested in seeing that patient-level data. What we’re interested in is, can the FDA make a regulatory decision on signals?”
Commissioner Makary said 45% of the time between Phase 1 start and approval submission is “dead time” (i.e. paperwork, analysis, formatting, and the gaps between discrete phase). He framed this explicitly as a competitiveness issue: China surpassed the U.S. in Phase 1 trial volume around 2021, and the growth since has been “exponential.” The stated ambition goes beyond speed — it’s about collapsing the traditional Phase 1 → 2 → 3 sequence into “continuous trials” by eliminating inter-phase hiatuses.
🧠 BPS Take: This is the most concrete output of the Makary FDA push to modernize the agency and use technology to speed up drug reviews. Name-dropping AstraZeneca and Amgen signals credibility and that Big Pharma sees value in the transparency-for-speed trade. But the real test is whether this scales beyond these two oncology indications, how these scale up to larger studies, and later on into other therapeutic areas.
The China point Makary makes is an important one too. Seeing how quickly China has outpaced the US in clinical trials, as well as the plethora of deals by US based entities to bring-in Chinese drugs, is serving as a helpful counterpoint to show how our systems can be improved. It’s rare in our political culture to look at other countries and think, “hey they seem to know what they’re doing over there, let’s try that at home” from a place of abundance. Instead we respond best to competition. The fear that we are falling behind in drug development, AI, and energy comes from a place of scarcity, but perhaps America’s love language is competition, and China knows just how to pull on our heart strings.
The Lp(a) Drug Race: Novartis’ Pelacarsen (Lp(a)HORIZON, 8,323 pts), Amgen’s Olpasiran, Eli Lilly’s Muvalaplin — H1 2026 Outcomes Data Imminent
📅 Date: April 27, 2026 (feature week) | 🏢 Company: Novartis ( NVS 0.00%↑ ) / Ionis ( IONS 0.00%↑ ) / Amgen ( AMGN 0.00%↑ ) / Eli Lilly ( LLY 0.00%↑ ) | 💊 Drug/Asset: Pelacarsen (ASO, Lp(a)HORIZON Phase 3); Olpasiran/AMG-890 (siRNA, OCEAN Phase 3); Muvalaplin (oral small molecule, Phase 3) | 🏷 Event Type: Industry Feature — Late-Stage CV Outcomes Race
CNBC highlighted three major pharmaceutical companies racing to prove that lowering lipoprotein(a) (Lp(a)) reduces cardiovascular events, with pivotal outcomes data expected in the first half of 2026. Novartis and Ionis are leading with pelacarsen, an antisense oligonucleotide (ASO), in the Lp(a)HORIZON trial enrolling 8,323 patients. Topline results are expected in H1 2026. Amgen is running the OCEAN(a)-OUTCOME Phase 3 trial with olpasiran, an siRNA. Eli Lilly is developing muvalaplin, an oral small molecule that inhibits Lp(a) formation, currently in Phase 3.
Approximately 64 million Americans have elevated Lp(a), and there is currently no approved therapy specifically targeting this risk factor. Elevated Lp(a) is an independent cardiovascular risk factor associated with increased rates of heart attack and stroke, even in patients with well-controlled LDL cholesterol.
🧠 BPS Take: The H1 2026 outcomes data from Lp(a)HORIZON is the pivotal proof-of-concept for the entire Lp(a) field. Lowering Lp(a) does not automatically equal reducing cardiovascular events, but most KOLs will tell you they feel pretty good that doing so will reduce cardiac events. Still, this needs to be be proven in a large, adequately powered outcomes trial. Lp(a)HORIZON with 8,323 patients is the first trial designed to answer that question. If pelacarsen hits, it serves as a sigh of rlief to the whole field, validating this target as a key lever for cholesterol control and opening the competitive gates for the rest of the Lp(a) programs to follow suit. If it misses, the conversation shifts to whether Lp(a) needs to be pushed down even further in order to see hard outcomes benefits. Right now pelacarsen has demonstrated 80% reduction in P2 studies. Olpasiran (Amgen) and Lepodisiran (Lilly) have shown 95% and 94% respectively.
Lilly again has a sharp strategy in this arena. They aren’t sticking to just siRNA based treatment, as they have an oral Lp(a) inhibitor, muvalaplin, now enrolling a P3 outcomes study. As we’ve seen with the PCSK9 market, it has taken a long time for injectables (whether they be antibodies or siRNA) to gain market traction. For cholesterol control, it’s possible oral convenience may hold the advantage for commercial uptake.
As an aside, I was pleased to see Lp(a) get attention on a more generalist site like CNBC. I feel pretty confident Lp(a) reduction is clinically meaningful. Just hearing so many stories from cardiologist friends of mine of very young people dying of heart attacks, not knowing why, only to later find out that they were genetically predisposed to having very high Lp(a). The annoying part about this is that even if these trials read out positively, it is going to take some time for guidelines to change and for clinical practice to change to regularly test for it. Right now, even for LDL, we just get our LDL-c measured in our annual checkups, when it is pretty clear that ApoB100 is a much better measure of your bad cholesterol related risk.
In any case, if you are curious about your genetic predisposition to high Lp(a), you can go pay for a test yourself (as I did) at the behest of one my cardiologist friends. South Asians and African Americans tend to be the most at risk, thus why I felt the need to get mine checked out. Thankfully I am A-OK, but even if I wasn’t, I am excited that there will be new drugs soon that help to prevent Lp(a) related cardiac events.
Semaglutide Cuts Heavy Drinking by 41% in Lancet RCT — GLP-1s Open Another Therapeutic Front
📅 May 1 | 🏢 Novo Nordisk ( NVO 0.00%↑ ) | 💊 Semaglutide (Wegovy) | 🏷️ Data Readout
A randomized, double-blind, placebo-controlled trial published in The Lancet showed once-weekly semaglutide 2.4 mg reduced heavy drinking days by 13.7 percentage points more than placebo over 26 weeks in 108 adults with obesity and alcohol use disorder. Semaglutide also reduced total alcohol consumption (467.5 g/30 days difference), drinks per drinking day, self-reported cravings, and multiple alcohol biomarkers including phosphatidylethanol (p<0.0001). Safety was consistent with known GI side effects. The trial was conducted at Mental Health Center Copenhagen and funded in part by Novo Nordisk.
🧠 BPS Take: The anecdotal evidence has been accumulating for years. Now there’s a properly controlled Lancet RCT confirming it. GLP-1s reduce alcohol consumption. Importantly, this was a small trial (n=108), in patients with both obesity and alcohol use disorder, at a single site in Denmark. Less than 2% of people with alcohol use disorder in the U.S. use pharmacotherapy. If larger trials replicate this, Novo and Lilly have a potential indication that could expand GLP-1 addressable market well beyond obesity and diabetes into behavioral health. That’s exactly what Lilly is betting on with brenipatide, its once-monthly GLP-1/GIP agonist. The key question that remains for me is that will this still work in patients who are not obese? What does this say about breaking addiction to other vices that are not calorie-driven or food-like (e.g. smoking, opioids, etc.)?
💰 FOLLOW THE MONEY
Deals, dollars, and what they signal
M&A Bundle: Sun/Organon $11.75B (India’s Largest US Pharma Acquisition) + Lilly/Ajax $2.3B (Type II JAK2) + Ligand/XOMA $739M (Royalty Aggregation)
📅 Date: April 26-27, 2026 | 🏢 Company: Sun Pharmaceutical Industries / Organon ( OGN 0.00%↑ ); Eli Lilly ( LLY 0.00%↑ ) / Ajax Therapeutics; Ligand Pharmaceuticals ( LGND 0.00%↑ ) / XOMA Royalty ( XOMA 0.00%↑ ) | 💊 Drug/Asset: Organon portfolio (Nexplanon, biosimilars, legacy brands); AJX-101 (Type II JAK2 inhibitor, Phase 1); XOMA royalty portfolio (200+ assets, 7 commercial) | 🏷 Event Type: Acquisition (All-Cash x2; Milestone-Based x1)
Sun Pharmaceutical Industries announced a definitive agreement to acquire Organon for $14.00 per share in cash, representing a 24% premium and an enterprise value of $11.75B. The deal, announced Saturday evening April 26, is India’s largest-ever acquisition of a U.S. pharmaceutical company. Organon’s portfolio includes Nexplanon (the #1 contraceptive implant in the U.S.), a biosimilars business, and legacy women’s health brands. The transaction is expected to close in early 2027, making Sun Pharma the third-largest global women’s health company.
Eli Lilly announced on April 27 that it will acquire Ajax Therapeutics for up to $2.3B in milestone payments. Ajax is developing AJX-101, a Type II JAK2 inhibitor in Phase 1 for myelofibrosis and polycythemia vera. Type II JAK2 inhibitors represent a mechanistic differentiation from all currently approved JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib), which are Type I. This is Lilly’s sixth acquisition of 2026.
Ligand Pharmaceuticals announced on April 27 that it will acquire XOMA Royalty for $39.00 per share in cash, representing approximately a 3% premium and an equity value of $739M. The combined entity will hold royalty interests in over 200 partnered programs, including seven commercial products. The transaction is expected to close in Q3 2026.
🧠 BPS Take: Three completely different M&A logics playing out in the same 48-hour window.
Sun Pharma is making a bold move, signaling that they are not satisfied staying in India, and want to have a foothold in the US market and expanding its business into speciality areas, like women’s health. Raising $7.75B in debt to take out Organon could either be really smart or look really dumb in retrospect. Still, this is a major sign that one of India’s largest drug makers is ready to make waves in the US specialty market. Organon gives them a top-3 global women’s health franchise, a U.S. commercial infrastructure, and a biosimilars platform.
Lilly is buying yet another early clinical phase asset, this time a Type II JAK2 inhibitor for myelofibrosis. The idea here is that this strategy may overcome resistance mechanisms seen with Type I inhibitors (ruxolitinib, etc.). It still baffles me that for all the innovation we have had in oncology, myelfoibrosis is still treated largely with a series of slightly different flavors of JAK inhibitors. Nonetheless, here is Lilly continuing its trend of taking multiple shots on goal on early science well-before any of their GLP-1 patent cliffs hit. If AJX-101 shows activity in post-ruxolitinib myelofibrosis patients, this could quickly climb the JAK inhibitor hierarchy. If it doesn’t, Lilly writes off the milestones and moves on. A billion or two here and there as a write-off is just chump change for them.
Ligand/XOMA is pure financial engineering, aggregating royalty streams as an asset class. Post-deal, Ligand will have 200+ royalty assets generating predictable cash flows with minimal operational risk. These royalty businesses have done incredibly well and might be a win-win for later-stage biotechs, giving them a lifeline to large amounts of upfront non-dilutive capital. Notably Revolution Medicines RVMD 0.00%↑ did a royalty financing deal back in June 2025 with Royalty Pharma, netting them $2B upfront in exchange for tiered declining royalties on daraxonrasib for 15 years. The royalties drop to zero once annual sales exceed $8B. All signs point to them meeting or exceeding that mark. Owl Posting had a nice deep dive on these sorts of synthetic royalty deals and other methods of financial engineering in Biotech that I highly recommend reading if you want to learn more about this topic and how it fits into the broader architecture of innovation.
Triple Biotech IPO Surge: Seaport $255M (SPTX), Hemab $302M (COAG), Avalyn $300M (AVLN, +44% debut) — $850M+ Raised, Strongest Market Since 2021
📅 Date: April 27-30, 2026 (week) | 🏢 Company: Seaport Therapeutics ( SPTX 0.00%↑ ) / Hemab Therapeutics Holdings ( COAG 0.00%↑ ) / Avalyn Pharma ( AVLN 0.00%↑ ) | 💊 Drug/Asset: Seaport neuropsychiatry pipeline (PureTech spinout); Hemab coagulation portfolio (Glanzmann thrombasthenia, Von Willebrand Disease); Avalyn inhaled IPF treatments | 🏷 Event Type: Triple Biotech IPO Pricing — All Three Upsized
Three biotech companies priced upsized IPOs during the week of April 27, collectively raising over $850M and signaling the strongest biotech IPO market since 2021. Seaport Therapeutics raised $255M by pricing 14.16 million shares at $18, upsized from an initial target of $212.4M. The company, a PureTech spinout, is developing a neuropsychiatry pipeline. Hemab Therapeutics Holdings raised $301.5M by pricing 16.75 million shares at $18, upsized from an initial target of $200M. The company, backed by Novo Holdings, is developing treatments for rare coagulation disorders including Glanzmann thrombasthenia and Von Willebrand Disease.
Avalyn Pharma raised $300M at $18 per share and surged 44% on its debut to close at $26, giving the company a market capitalization of approximately $1.1B. Avalyn, also backed by Novo Holdings, is developing reformulated inhaled treatments for idiopathic pulmonary fibrosis (IPF). The three IPOs bring Q1 2026 total biotech IPO proceeds to approximately $2.2B, according to industry trackers.
🧠 BPS Take: These three IPOs are a strong sign that the IPO window is open and public market investors have an appetite for mid to late stage drug companies again. A psych company, a pulmonary disease company, and a rare disease company, quite a diverse grouping, all doing well on their first days of trading is a signal that investors are willing to take risk across many therapeutic areas, and not just the hot areas like GLP-1s. Watch for more IPOs in Q2 2026 if this momentum holds.
Back next week with more BioPharma strategy takes! Share this with a friend of colleague if you found it helpful.